JP2013542185A5 - - Google Patents

Download PDF

Info

Publication number
JP2013542185A5
JP2013542185A5 JP2013528356A JP2013528356A JP2013542185A5 JP 2013542185 A5 JP2013542185 A5 JP 2013542185A5 JP 2013528356 A JP2013528356 A JP 2013528356A JP 2013528356 A JP2013528356 A JP 2013528356A JP 2013542185 A5 JP2013542185 A5 JP 2013542185A5
Authority
JP
Japan
Prior art keywords
protein
polypeptide
transcription
factor
high mobility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013528356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542185A (ja
JP6012603B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/051107 external-priority patent/WO2012034090A1/en
Publication of JP2013542185A publication Critical patent/JP2013542185A/ja
Publication of JP2013542185A5 publication Critical patent/JP2013542185A5/ja
Application granted granted Critical
Publication of JP6012603B2 publication Critical patent/JP6012603B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013528356A 2010-09-09 2011-09-09 バイオフィルムを除去するための組成物および方法 Active JP6012603B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38137710P 2010-09-09 2010-09-09
US61/381,377 2010-09-09
PCT/US2011/051107 WO2012034090A1 (en) 2010-09-09 2011-09-09 Compositions and methods for the removal of biofilms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015193476A Division JP2016000760A (ja) 2010-09-09 2015-09-30 バイオフィルムを除去するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013542185A JP2013542185A (ja) 2013-11-21
JP2013542185A5 true JP2013542185A5 (https=) 2014-09-25
JP6012603B2 JP6012603B2 (ja) 2016-10-25

Family

ID=44654515

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013528356A Active JP6012603B2 (ja) 2010-09-09 2011-09-09 バイオフィルムを除去するための組成物および方法
JP2015193476A Withdrawn JP2016000760A (ja) 2010-09-09 2015-09-30 バイオフィルムを除去するための組成物および方法
JP2017122250A Active JP6420417B2 (ja) 2010-09-09 2017-06-22 バイオフィルムを除去するための組成物および方法
JP2018081136A Withdrawn JP2018111731A (ja) 2010-09-09 2018-04-20 バイオフィルムを除去するための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015193476A Withdrawn JP2016000760A (ja) 2010-09-09 2015-09-30 バイオフィルムを除去するための組成物および方法
JP2017122250A Active JP6420417B2 (ja) 2010-09-09 2017-06-22 バイオフィルムを除去するための組成物および方法
JP2018081136A Withdrawn JP2018111731A (ja) 2010-09-09 2018-04-20 バイオフィルムを除去するための組成物および方法

Country Status (6)

Country Link
US (2) US20120128701A1 (https=)
EP (1) EP2613797B1 (https=)
JP (4) JP6012603B2 (https=)
AU (1) AU2011299025B2 (https=)
CA (1) CA2810851C (https=)
WO (1) WO2012034090A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
MX2012010793A (es) * 2010-03-29 2013-05-09 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas.
EP2613797B1 (en) 2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
CA2915210A1 (en) * 2013-06-13 2014-12-18 Research Institute At Nationwide Children's Hospital Compositions and methods for the treatment of burkholderia infections
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
AU2015227075A1 (en) 2014-03-06 2016-09-22 Ohio State Innovation Foundation Probiotic formulations and methods for use
WO2016154491A1 (en) * 2015-03-25 2016-09-29 Trellis Bioscience, Llc Binding moieties for biofilm remediation
WO2017011588A1 (en) 2015-07-14 2017-01-19 Research Institute At Nationwide Children's Hospital Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Dnabiiワクチンおよび強化された活性を有する抗体
AU2018206560B9 (en) 2017-01-04 2025-04-03 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
US11969459B2 (en) 2017-01-27 2024-04-30 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
AU2018236271B2 (en) 2017-03-15 2023-12-21 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CA3084013A1 (en) 2017-12-01 2019-06-06 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
WO2019107530A1 (ja) 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
JP6641420B2 (ja) 2018-06-12 2020-02-05 株式会社アマダホールディングス 分割金型の装着方法及びプレスブレーキ
JP7235776B2 (ja) * 2018-06-12 2023-03-08 テルモ カーディオバスキュラー システムズ コーポレイション 心血管弁処置のための円形リトラクタ
SG11202103001PA (en) * 2018-10-05 2021-04-29 Res Inst Nationwide Childrens Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
US12569524B2 (en) 2018-10-22 2026-03-10 Research Institute At Nationwide Children's Hospital Compositions and methods for preventing and treating antibiotic induced pathologies using probiotics in the biofilm state
US12521423B2 (en) 2019-02-26 2026-01-13 The Regents Of The University Of Colorado, A Body Corporate Method and composition for treating gastrointestinal inflammatory disorders
WO2020247536A1 (en) 2019-06-03 2020-12-10 Research Institute At Nationwide Children's Hospital Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
WO2021007260A2 (en) 2019-07-08 2021-01-14 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
WO2025106896A1 (en) * 2023-11-17 2025-05-22 Rush University Medical Center Coating of medical and implant biomaterials with an anti-biofilm agent to prevent and treat infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6355450B1 (en) 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US20050131222A1 (en) 1995-04-21 2005-06-16 Human Genome Sciences, Inc. Nucleotide sequence of the haemophilus influenzae Rd genome, fragments thereof, and uses thereof
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US20020042386A1 (en) * 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2004001058A2 (en) 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
EP1392844A4 (en) * 2001-05-15 2006-09-06 Long Island Jewish Res Inst USE OF HMG FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
JP4511173B2 (ja) 2001-08-24 2010-07-28 マイジェニックス インコーポレイテッド 抗菌性および抗炎症性ペプチド
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US20030099602A1 (en) 2001-10-25 2003-05-29 Levin Gilbert V. D-tagatose as an anti-biofilm agent
EP1524991A1 (en) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
JP2006506441A (ja) * 2002-11-20 2006-02-23 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト 免疫応答を増大させるためのhmgbポリペプチドの使用
DE60333228D1 (de) 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
EP1579221A2 (de) * 2003-01-03 2005-09-28 Alcedo Biotech GmbH Verwendungen von hmgb, hmgn, hmga proteinen
US7297340B2 (en) 2003-01-07 2007-11-20 University Of Iowa Research Foundation Vaccine and method for preventing biofilm formation
EP1592707A2 (en) * 2003-02-14 2005-11-09 Fondazione Centro San Raffaele Del Monte Tabor Hmgb1 modulator binding domain
CA2796381A1 (en) 2003-03-06 2004-09-16 Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable haemophilus influenzae
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
AU2005226420A1 (en) 2004-03-26 2005-10-06 Locomogene, Inc. Decoy nucleic acid to synoviolin gene promoter
WO2006083301A2 (en) * 2004-06-17 2006-08-10 Medimmune, Inc. Immunogenic compositions comprising hmgb1 polypeptides
US20060030539A1 (en) 2004-08-06 2006-02-09 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
US7585504B2 (en) 2004-10-22 2009-09-08 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
US20060228384A1 (en) 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
CA2642754A1 (en) 2006-02-13 2007-08-23 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
PL2061886T3 (pl) 2006-08-21 2014-10-31 Univ British Columbia Małe kationowe peptydy immunomodulujące
EP1980269A1 (en) 2007-04-13 2008-10-15 Katholieke Universiteit Leuven Prevention of staphylococcus biofilm formation
MX2012010793A (es) * 2010-03-29 2013-05-09 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas.
EP2613797B1 (en) 2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms
CA2915210A1 (en) 2013-06-13 2014-12-18 Research Institute At Nationwide Children's Hospital Compositions and methods for the treatment of burkholderia infections
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections

Similar Documents

Publication Publication Date Title
JP2013542185A5 (https=)
US20250099422A1 (en) Compositions and methods for treating allergic inflammatory conditions
JP2019526611A5 (https=)
JP2018512454A5 (https=)
BR0316082A (pt) Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit
BR0309837A (pt) Forma de administração trans-epicutânea para tratamento da sìndrome das pernas inquietas
BRPI0514420A (pt) peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo
MA32539B1 (fr) Traitement du diabète chez des patients pour lesquels une thérapie par la metformine n'est pas appropriée
JP2021504390A5 (https=)
JP2015520188A5 (https=)
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
WO2010124283A4 (en) Methods and compositions relating to hematologic malignancies
JP2017526627A5 (https=)
JP2015514778A5 (https=)
JP4234439B2 (ja) Il−12発現調節剤
BR112014004587A2 (pt) combinações sinérgicas de inibidores de pi3k- e de mek
JP2020524689A5 (https=)
WO2006078424A3 (en) Polyherbal compositions and methods for treating viral infections
Velliyagounder et al. Oral lactoferrin protects against experimental candidiasis in mice
Zhang et al. Noval advance of histone modification in inflammatory skin diseases and related treatment methods
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
TWI351950B (en) Use of (halobenzyloxy) benzylamino-propanamides fo
Krämer et al. Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
JP4290764B2 (ja) ヒトおよび動物のボルナ病ウイルスへの感染防止、ならびに情動障害およびbdv感染に関連するその他の障害の予防および治療に対するアダマンタンアミンまたはその構造的類縁化合物の使用